ES2118557T3 - Compuestos de isoxazolina como inhibidores de la liberacion de tnf. - Google Patents

Compuestos de isoxazolina como inhibidores de la liberacion de tnf.

Info

Publication number
ES2118557T3
ES2118557T3 ES95906459T ES95906459T ES2118557T3 ES 2118557 T3 ES2118557 T3 ES 2118557T3 ES 95906459 T ES95906459 T ES 95906459T ES 95906459 T ES95906459 T ES 95906459T ES 2118557 T3 ES2118557 T3 ES 2118557T3
Authority
ES
Spain
Prior art keywords
disease
inhibitors
isoxazoline compounds
compounds
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95906459T
Other languages
English (en)
Inventor
Victoria L Cohan
Edward F Kleinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2118557T3 publication Critical patent/ES2118557T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE ISOXAZOLINA DE FORMULA (I) LOS CUALES SON INHIBIDORES DEL FACTOR DE LA NECROSIS TUMORAL (FNT). LOS COMPUESTOS DE ISOXAZOLINA SON UTILES PARA INHIBIR EL FNT EN UN MAMIFERO QUE NECESITE DE ELLO Y EN EL TRATAMIENTO O ATENUACION DE LAS AFECCIONES O ENFERMEDADES INFLAMATORIAS, INCLUYENDO PERO NO LIMITADOS A LA ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, BRONQUITIS, ENFERMEDAD CRONICA DE OBSTRUCCION DE LOS CONDUCTOS RESPIRATORIOS, PSORIASIS, RINITIS ALERGICA, DERMATITIS, ENFERMEDAD DE INFLAMACION DEL INTESTINO, SEPSIS, CONMOCION SEPTICA, TUBERCULOSIS, ENFERMEDAD DEL INJERTO CONTRA EL HUESPED Y CAQUEXIA ASOCIADA CON EL SIDA O EL CANCER. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS UTILES PARA LOS MISMOS QUE COMPRENDEN TALES COMPUESTOS DE LA FORMULA (I) EN DONDE X{SUP,1} ES -(CH{SUB,2}){SUB,Q}OH, CHOHR{SUP,5} O -(CH{SUB,2}){SUB,M}CON(R{SUP,6})(OH); EN DONDE Q Y U SON CADA UNO INDEPENDIENTEMENTE O O UN NUMERO ENTERO DE 1 A 5; R{SUP,5} ES ALQUILO(C{SUB,1}-C{SUB,4}); Y R{SUP,6} ES HIDROGENO O ALQUILO (C{SUB,1}-C{SUB,3}); N ES 0, 1, 2 O 3; Y{SUP,1} Y Y{SUP,2} SON COMO SE DEFINEN EN LA APLICACION.
ES95906459T 1994-03-09 1995-02-03 Compuestos de isoxazolina como inhibidores de la liberacion de tnf. Expired - Lifetime ES2118557T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20912594A 1994-03-09 1994-03-09

Publications (1)

Publication Number Publication Date
ES2118557T3 true ES2118557T3 (es) 1998-09-16

Family

ID=22777444

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95906459T Expired - Lifetime ES2118557T3 (es) 1994-03-09 1995-02-03 Compuestos de isoxazolina como inhibidores de la liberacion de tnf.

Country Status (18)

Country Link
US (2) US5869511A (es)
EP (1) EP0749428B1 (es)
JP (1) JPH09505082A (es)
KR (1) KR100200449B1 (es)
CN (1) CN1143363A (es)
AT (1) ATE169009T1 (es)
AU (1) AU684887B2 (es)
CA (1) CA2185019C (es)
DE (1) DE69503769T2 (es)
DK (1) DK0749428T3 (es)
ES (1) ES2118557T3 (es)
FI (1) FI963510A0 (es)
IL (1) IL112847A (es)
MY (1) MY114667A (es)
NO (1) NO310496B1 (es)
NZ (1) NZ278667A (es)
WO (1) WO1995024398A1 (es)
ZA (1) ZA951909B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022977A (en) 1997-03-26 2000-02-08 Dupont Pharmaceuticals Company Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
EP0998468A1 (de) * 1997-07-23 2000-05-10 Basf Aktiengesellschaft Substituierte 3-phenylisoxazoline
AU9198698A (en) * 1997-09-15 1999-04-05 Warner-Lambert Company Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
ES2255294T3 (es) 1998-08-07 2006-06-16 Chiron Corporation Derivados de isoxazol sustituidos como moduladores del receptor de estrogenos.
ES2216579T3 (es) 1998-10-09 2004-10-16 Janssen Pharmaceutica N.V. Derivados de 4,5-dihidro-isoxazol y su uso farmaceutico.
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
JP4195561B2 (ja) * 1999-09-17 2008-12-10 エルジー ケム インヴェストメント リミティッド カスパーゼインヒビター
KR100399361B1 (ko) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 캐스파제 억제제 함유 치료제 조성물
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0021776D0 (en) * 2000-09-05 2000-10-18 Arakis Ltd The treatment of inflammatory disorders
EP1411930B1 (en) * 2001-06-08 2013-01-16 Cytokine Pharmasciences, Inc. Isoxazoline compounds having mif antagonist activity
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
AU2003301903A1 (en) * 2002-11-06 2004-06-03 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
JP2006517191A (ja) * 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
ES2526614T3 (es) 2004-03-05 2015-01-13 Nissan Chemical Industries, Ltd. Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
CA2557166C (en) * 2004-03-26 2015-06-30 Cytokine Pharmasciences, Inc. Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
BRPI0511070A (pt) 2004-06-17 2007-11-27 Infinity Pharmaceuticals Inc compostos e processos para inibição da interação de proteìnas bcl com parceiros de ligação
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
CN103156845B (zh) * 2005-03-15 2015-11-18 翁科诺克斯有限公司 具有免疫调节活性的化合物
JP5152518B2 (ja) 2006-03-10 2013-02-27 日産化学工業株式会社 置換イソキサゾリン化合物及び有害生物防除剤
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
CA2686766A1 (en) * 2007-05-09 2008-11-20 Ganial Immunoterapeutics Inc. (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
AU2010213936B2 (en) * 2009-02-10 2014-07-31 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
US20150064221A1 (en) 2012-04-17 2015-03-05 Niranjan Y. Sardesai Compounds having immunomudulator activity
CN102911131B (zh) * 2012-10-24 2014-10-29 中化蓝天集团有限公司 一种双键桥三氟甲基异噁唑类化合物、其制备方法及应用
RU2685234C1 (ru) * 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995048A (en) * 1975-10-20 1976-11-30 Sandoz, Inc. Isoxazolyl benzamides useful as tranquilizers and sleep-inducers
US4112108A (en) * 1976-12-06 1978-09-05 Sandoz, Inc. Isoxazolyl benzamides
JPS5512038A (en) * 1978-07-07 1980-01-28 Ube Industries Packing sack made of flat thread made from resin film
JPS55104273A (en) * 1979-02-05 1980-08-09 Sankyo Co Ltd 4-phenylisoxazole derivative and its preparation
CA1128526A (en) * 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
HU215433B (hu) * 1986-04-29 2000-05-28 Pfizer Inc. Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására
US4892870A (en) * 1988-08-01 1990-01-09 Biofor, Ltd. Oxaza heterocycles and pharmaceutical compositions containing same
FR2639636B1 (fr) * 1988-11-30 1994-03-04 Novapharme Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
DE3914969A1 (de) * 1989-05-02 1990-11-08 Schering Ag 5-substituierte 3-arylisoxazol-derivate, deren herstellung und verwendung als schaedlingsbekaempfungsmittel
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
AU6355190A (en) * 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5051438A (en) * 1990-05-16 1991-09-24 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof, compositions and use
DE4016049A1 (de) * 1990-05-18 1991-11-21 Basf Ag 3-isoxazolylbenzylester, ihre herstellung und ihre verwendung
EP0557408A4 (en) * 1990-11-06 1993-10-27 Smith-Kline Beecham Corporation Imidazolidinone compounds
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
JP2702833B2 (ja) * 1991-10-09 1998-01-26 松下電器産業株式会社 レーザ加工装置
CN1046274C (zh) * 1993-11-26 1999-11-10 辉瑞大药厂 用作消炎剂的异噁唑啉化合物

Also Published As

Publication number Publication date
EP0749428B1 (en) 1998-07-29
DE69503769D1 (de) 1998-09-03
NO310496B1 (no) 2001-07-16
JPH09505082A (ja) 1997-05-20
CA2185019C (en) 2000-08-08
AU684887B2 (en) 1998-01-08
WO1995024398A1 (en) 1995-09-14
KR100200449B1 (ko) 1999-06-15
ZA951909B (en) 1996-09-09
DE69503769T2 (de) 1998-12-03
NO963746L (no) 1996-11-06
FI963510A (fi) 1996-09-06
AU1464795A (en) 1995-09-25
NO963746D0 (no) 1996-09-06
US6114367A (en) 2000-09-05
CN1143363A (zh) 1997-02-19
DK0749428T3 (da) 1998-11-16
MY114667A (en) 2002-12-31
FI963510A0 (fi) 1996-09-06
MX9603975A (es) 1997-09-30
EP0749428A1 (en) 1996-12-27
NZ278667A (en) 2000-12-22
IL112847A (en) 1999-10-28
US5869511A (en) 1999-02-09
ATE169009T1 (de) 1998-08-15
IL112847A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
ES2118557T3 (es) Compuestos de isoxazolina como inhibidores de la liberacion de tnf.
MX9504020A (es) Compuestos de catecol dieter como inhibidores de la liberacion de factor de necrosis tumoral.
ES2139754T3 (es) 3-fenil-2-isoxazolinas como agentes antiinflamatorios.
ES2154683T3 (es) Indoles sustituidos como inhibidores de fosfodiesterasa de tipo iv.
BR9408174A (pt) Compostos isoxazolina como agentes antiinflamatórios
DE69813895D1 (de) Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung
HK1051691A1 (en) Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition
WO2008071605A3 (en) Methods of treating inflammatory diseases
DK0980374T3 (da) Phosphodiesterase 4-inhiberende diazepinoindoloner.
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
MY112586A (en) Isoxazoline compounds as 5-lipoxygenase inhibitors
CL2008002853A1 (es) Compuestos derivados de piraziin quinolina sustituida, inhibidores de la migracion de macrofagos (mif); y su uso en el tratamiento de inflamacion, shock septico, artritis, cancer, trastornos autoinmunes e inhibicion de angiogenesis (divisional de la solicitud 1088-02)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 749428

Country of ref document: ES